Susquehanna Fundamental Investments LLC purchased a new stake in shares of Invivyd, Inc. (NASDAQ:IVVD – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 104,732 shares of the company’s stock, valued at approximately $115,000. Susquehanna Fundamental Investments LLC owned 0.09% of Invivyd as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also modified their holdings of the company. Duquesne Family Office LLC bought a new position in Invivyd in the 2nd quarter valued at about $629,000. Acadian Asset Management LLC boosted its holdings in shares of Invivyd by 232.0% in the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock valued at $745,000 after acquiring an additional 474,301 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Invivyd in the second quarter valued at approximately $421,000. Bank of New York Mellon Corp bought a new stake in Invivyd during the second quarter worth approximately $263,000. Finally, Dimension Capital Management LLC raised its holdings in Invivyd by 243.3% during the second quarter. Dimension Capital Management LLC now owns 189,871 shares of the company’s stock worth $209,000 after purchasing an additional 134,571 shares in the last quarter. 70.36% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Invivyd in a research report on Tuesday, September 3rd.
Invivyd Trading Down 1.1 %
NASDAQ:IVVD opened at $0.95 on Friday. The company has a 50-day moving average of $1.02 and a 200-day moving average of $1.73. The firm has a market cap of $113.41 million, a price-to-earnings ratio of -0.51 and a beta of 0.63. Invivyd, Inc. has a twelve month low of $0.81 and a twelve month high of $5.20.
Invivyd (NASDAQ:IVVD – Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.03). The company had revenue of $2.26 million for the quarter, compared to analyst estimates of $4.91 million. On average, research analysts forecast that Invivyd, Inc. will post -0.6 earnings per share for the current year.
Invivyd Profile
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
See Also
- Five stocks we like better than Invivyd
- What is a Secondary Public Offering? What Investors Need to Know
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- How to Calculate Retirement Income: MarketBeat’s Calculator
- MarketBeat Week in Review – 9/30 – 10/4
- What is a Low P/E Ratio and What Does it Tell Investors?
- Top Streaming Companies: Who’s Winning the Battle?
Want to see what other hedge funds are holding IVVD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invivyd, Inc. (NASDAQ:IVVD – Free Report).
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
